title: Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib.
authors: Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
authors: Massimo
authors: M
authors: Breccia
authors: Gioia
authors: G
authors: Colafigli
authors: Matteo
authors: M
authors: Molica
authors: Giuliana
authors: G
authors: Alimena
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications* / Q000473:pathology / Q000517:prevention & control; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; C498826:nilotinib